Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Ovarian Neoplasms 7Fallopian Tube Neoplasms 6Carcinoma 2Sarcoma, Endometrial Stromal 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Kidney Neoplasms 1Colorectal Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

pembrolizumab 10Filgrastim 7Ifosfamide 4Carboplatin 4aldesleukin 3Temozolomide 3Peripheral Blood Stem Cell Transplantation 3Drug Therapy 3Docetaxel 3Cyclophosphamide 3Counseling 3fludarabine phosphate 2fludarabine 2etoposide phosphate 2cemiplimab 2belinostat 2atezolizumab 2Thiotepa 2Surveys and Questionnaires 2Radiotherapy 2Nivolumab 2Methods 2Metformin 2Early Intervention, Educational 2Doxorubicin 2Bupropion 2Blood Specimen Collection 2Amifostine 23-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 2valspodar 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Kidney Neoplasms × trebananib × Gynecologic × Clear all
NCT03239145 2026-03-12

Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

Dana-Farber Cancer Institute

Phase 1 Completed
62 enrolled 17 charts
DermatologicGastrointestinalGenitourinaryGynecologic

Kidney Neoplasms, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡